Sinopharm needs trial results to decide if COVID-19 shot needs booster – executive

PUBLISHED: Sun, 28 Mar 2021 07:36:44 GMT

BEIJING, March 28 (Reuters) – China National Pharmaceutical Group (Sinopharm) will need to assess results from Phase III clinical trials to decide whether its two-shot COVID-19 vaccine should be followed by a booster shot, Zhang Yuntao, vice president at China National Biotec Group (CNBG), an affiliate of Sinopharm, said on Sunday.

Antibodies triggered by two COVID-19 vaccine products from Sinopharm both have good neutralising effect on variants found in Britain and South Africa, Zhang told a news conference. (Reporting by Roxanne Liu and Ryan Woo; Editing by Simon Cameron-Moore)

(c) Copyright Thomson Reuters 2021. Click For Restrictions –

Sign Up for Our Newsletter Daily Update
Get the best of CNBC Africa sent straight to your inbox with breaking business news, insights and updates from experts across the continent.
Get this delivered to your inbox, and more info about about our products and services. By signing up for newsletters, you are agreeing to our Terms of Use and Privacy Policy.